Fagron NV (EBR: FAGR)

Market Cap	1.39B
Revenue (ttm)	820.76M
Net Income (ttm)	77.94M
Shares Out	72.99M
EPS (ttm)	1.07
PE Ratio	17.87
Forward PE	17.63
Dividend	0.30 (1.57%)
Ex-Dividend Date	May 21, 2024

Volume	17,608
Open	19.18
Previous Close	19.18
Day's Range	19.04 - 19.24
52-Week Range	15.45 - 20.05
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 19, 2024

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,647
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2023, Viohalco's revenue was 6.30 billion, a decrease of -9.79% compared to the previous year's 6.99 billion. Earnings were 48.23 million, a decrease of -81.88%.